SCFAs have been shown to improve insulin resistance (IR) by activating G-coupled protein receptors 41/43 (GPR41/43) in the intestine to promote the release of the gastrointestinal peptide hormones tyrosine peptide (PYY) and glucagon-like peptide 1 (GLP-1) from L-cells and reduce lipid intake by suppressing appetite (Psichas et al., 2015; Christiansen et al., 2018). This evidence concerns the gene GLP1R and Insulin resistance.